IA
RVLP

IFP Advisors’s RVL Pharmaceuticals plc Ordinary Shares RVLP Stock Holding History

IFP Advisors’s Portfolio RVLP Stock Details RVLP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-306
Closed -$2K – 4893
2022
Q3 		$2K Buy
+306
New +$594 ﹤0.01% 4454

Other funds holding RVLP

ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
RA
Rovida Advisors Fort Lauderdale, Florida $116M AUM 12.52% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

IFP Advisors's RVLP Position: Q4 2022 in Review

IFP Advisors sold out of RVL Pharmaceuticals plc Ordinary Shares (RVLP) in Q4 2022, closing a stake of 306 shares — an estimated $2K sold.

IFP Advisors first reported a position in RVLP in Q3 2022 and held it in 1 quarter. The position peaked at $2K in Q3 2022. 36 funds tracked by Wall St. Rank hold RVLP as of Q4 2022.

  • IFP Advisors reported no remaining RVL Pharmaceuticals plc Ordinary Shares position as of Q4 2022 after selling out during the quarter.
  • IFP Advisors sold 306 RVL Pharmaceuticals plc Ordinary Shares shares in Q4 2022, an estimated $2K.
  • IFP Advisors first reported a position in RVL Pharmaceuticals plc Ordinary Shares in Q3 2022 and held it in 1 quarter.
  • IFP Advisors's RVL Pharmaceuticals plc Ordinary Shares position peaked at $2K in Q3 2022.
  • 36 funds tracked by Wall St. Rank held RVL Pharmaceuticals plc Ordinary Shares as of Q4 2022.

Based on IFP Advisors's 13F filing for Q4 2022, filed 7 Feb 2023.